Epithelial-mesenchymal transition: A necessary new therapeutic target in chronic obstructive pulmonary disease? by Sohal SS et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Sohal SS, Eapen MS, Ward C, Walters EH. Epithelial mesenchymal transition 
(EMT): A necessary new therapeutic target in COPD?. American Journal of 
Respiratory and Critical Care Medicine 2017. DOI:  
 
 
Copyright: 
© American Thoracic Society 2017 
DOI link to article: 
https://doi.org/10.1164/rccm.201704-0771LE  
Date deposited:   
27/06/2017 
  
 1 
 
Epithelial mesenchymal transition (EMT): A necessary new therapeutic target in 
COPD? 
 
Sukhwinder Singh Sohal
1, 2
, Mathew Suji Eapen
1
, Chris Ward
1, 3
, Eugene Haydn Walters
1 
 
1
Breathe Well Centre of Research Excellence for Chronic Respiratory Disease and Lung 
Ageing, University of Tasmania, Hobart, Australia  
2
School of Health Sciences, University of Tasmania, Launceston, Australia  
3
Institute of Cellular Medicine, University of Newcastle Upon Tyne, UK 
 
Corresponding Author 
Dr Sukhwinder Singh Sohal 
School of Health Sciences, University of Tasmania 
Locked Bag – 1322, Newnham Drive 
Launceston, Tasmania 7248, Australia 
Telephone number: +61 3 6324 5434 
Email: sssohal@utas.edu.au 
 
 
Funding source: This work was supported by Clifford Craig Foundation 
 
 
 
 
 
 
 
 
 
 
 
Page 1 of 4  AJRCCM Articles in Press. Published on 22-June-2017 as 10.1164/rccm.201704-0771LE 
 Copyright © 2017 by the American Thoracic Society 
 2 
 
We read with interest the recent article by Jing Yang et al. in the American Journal of 
Respiratory and Critical Care Medicine (AJRCCM), considering smoking-induced small 
airway epithelial cell reprogramming, mediated by exaggerated EGF/EGFR signalling (1). 
Understanding of smoking-related COPD pathology is hugely important and has recently had 
a significant surge of new insights, and it is encouraging that leading respiratory journals are 
recognising this. However, we would like to suggest that a broader discussion of these new 
insights into COPD pathology might have been appropriate with this opportunity. In 
particular, a more integrated consideration of epithelial mesenchymal transition (EMT), its 
relationship to EGFR up-regulation, and perhaps the potential effects of inhaled 
corticosteroids (ICS) on these facets of COPD is urgently needed to aid discussion of this 
devastating pathophysiology.   
 
We and several other groups have demonstrated over recent years that both structurally and 
biochemically, there is active EMT present in the airway epithelium in COPD, in both large 
and small airways, and that this is closely related to airflow obstruction (2, 3). Furthermore, 
the Rbm and epithelium in large airways only is hyper-vascular (4) i.e. giving the classic 
appearance of active EMT type-III, which is a pre-malignant condition (5) which fits in with 
what we know about the excess risk if lung cancer in COPD. The other prime pathology 
associated with COPD is small airway fibrosis and obliteration, and this could potentially be 
related to active Type-II EMT at this site (2). We have shown that these processes are closely 
associated with epithelial EGFR hyper-expression, which may be major up-stream driver of 
such novel pathologies, which would fit with the suggestions being made by Yang et al (1) 
for a central place in COPD for EGFR. 
 
Further, we have reported in a pilot randomized controlled trial that inhaled corticosteroid 
fluticasone propionate given in high dose over six months suppressed EMT-related changes 
in large airways of COPD patients (6), along with suppression of EGFR expression. This is 
the first study reporting anti-EMT/EGFR effects of inhaled corticosteroids in COPD, where 
of course they are widely used as putative “anti-inflammatory” agent, modelled on their 
effects in eosinophilic asthma. In human epidemiological studies it is strongly suggested that 
patients on inhaled corticosteroids, albeit only at high doses (as used in our study), are 
associated with an appreciable (50%) reduction in the risk of lung cancer. We suggest EMT 
might be a process through which this effect of ICS occurs. If this is true, it has huge 
implications for therapeutic and public health policy, since it is strongly suggests that ICS or 
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some other agents having similar effects, should be given early in the natural history of 
COPD, not just to suppress airway luminal inflammation, but also to suppress epithelial 
activation, EMT and related fibrotic and malignant consequences.  
 
In summary, we are beginning to recognise that epithelial activation, basal cell 
reprogramming with EMT and vessel changes, may well represent fundamentally important 
aspects of COPD pathology in its broadest sense, including the severe sequelae of airway 
fibrosis and cancer development. At last, we may be getting into a position which allows an 
integrated understanding of this airway disease, with the potential to be translated into a new 
paradigm for earlier therapy attacking fundamental disease mechanisms rather than really 
only symptoms and clinical exacerbations in later-stage patients.  
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